MedTrace Logo

Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans

NCT04565067 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2026-01-14

No results posted yet for this study

Summary

Background:

The higher death rate from COVID-19 in the older population is associated with low CD8 T cell counts in the blood. Researchers want to learn the status of CD8 T cells specific to SARS-CoV-2 and their changes with aging and in COVID-19. This may help to identify why COVID-19 is particularly lethal in the elderly and help to create an effective vaccine against SARS-CoV-2 in the elderly.

Objective:

To identify SARS-CoV-2 specific CD8 T cells in humans, and to determine their quantity and quality in people who have recovered from COVID-19.

Eligibility:

Maryland residents age 18 and older who have tested positive for and recovered from COVID-19.

Design:

Participants will be screened by phone. They must be able to provide a copy of their positive COVID-19 test result.

Participants will visit the NIA/Clinical Research Unit. The visit will take about 1 hour.

Laboratory tests showing a positive COVID-19 result will be verified.

Participants vital signs will be checked. This will include blood pressure, temperature, pulse, and respiration. Height and weight will be measured.

Participants will have a medical history and medicine review. They will complete a COVID-19 questionnaire.

Participants will have blood drawn. They will give a urine sample.

Participants will give a saliva sample. They will rinse their mouth with water. After about 3 minutes, they will let saliva pool in the base of their mouth and then spit into a sterile container.

Participants may be asked if they would be willing to return for optional visits at about 4 months and 1 year later. They will repeat the same laboratory sampling performed at the first visit.

...

Conditions

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Nan-Ping P Weng, M.D. · National Institute on Aging (NIA)

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-22
Primary Completion
2026-12-31
Completion
2027-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04565067 on ClinicalTrials.gov